Francais
info@saveyourskin.ca

Save Your Skin Weekly Flashback! [September 12-18]

Welcome to the Save Your Skin Foundation media flashback- your weekly guide to the melanoma landscape, and the activities of the Save Your Skin Foundation! This week, we’re excited to announce our new educational video series, which we hope will answer your questions about a variety of skin cancer issues! There are already some videos up there, so be sure to check it out.

We’re also busy getting prepared for our upcoming public forum on October 6 in Nanaimo, B.C., hosted by Dermatologist Gabrielle Weichert, and melanoma survivors Nigel Deacon and Meloney Edgehill! More information can be found on the poster below.

PatientForumPoster_Oct2016

 

Here are some links we shared with you this week:

-This piece on immunotherapy in the Ottawa Citizen

-A link to the Canadian Daily UV Index Forecast

-A summary of our roundtable discussion about whether early detection and prevention in primary care can benefit patient outcomes

-This article on Entertainment Tonight Canada about Khloe Kardashian’s skin cancer scare!

-This piece on My Toba warning about the particular skin cancer risks for those over 50 years of age

-This article in the Ottawa Citizen about the hunt for immunotherapy funding

-And this lovely photo of two Save Your Skin Team members, Rose and Marion, who recently raced in Oregon wearing SYSF jerseys! Way to go, team!

systeam

 

Thank you for reading, and stay sun safe out there!

Read more

Daria’s Story

Toronto, ON

Just before the summer of 2015, I noticed a dark mole on my left calf. At first, I thought that something was stuck to my leg and tried to remove it in the shower. However, I realized it was actually a mole. I was almost certain that it was not there before.

While I was on summer vacation with my family, the mole made an appearance once again. My mom looked at my calf and said “Hey, you have a piece of chocolate stuck to your leg!” When I told her that it was a mole, she confirmed that she’s never seen it before and I need to check on it.

Three months after discovering the mole, I went to my doctor. He told me that the mole didn’t look good and we needed to cut it off and send it for analysis. Three weeks later I got my results from the lab and saw the diagnosis: “melanoma of SSM type, level 3, Breslow 0.36mm,” and then at the end the phrase “additional surgery is strongly recommended”.

I remember feeling scared and alone. I couldn’t understand what exactly the diagnosis meant and I didn’t know what to do next.

For several weeks my family and I were on a hunt for answers, trying to find what ‘strongly recommended’ really means, how urgent the problem is, and the main question ‘how serious it is’. During all that time I had a pressing thought in my head: “I have cancer cells in my leg and they might spread!”

I eventually got an appointment at Hospital Saint-Louis in Paris, France (where I lived at the time) which is recognized for being a top hospital to deal with melanomas. The amazing Dr. Madjlessi answered all of my questions, reassuring me that my case is one of the easiest as I caught it early enough. I got my surgery the next day to remove the remaining cancer tissue from my calf. Results of the surgery came in as expected – no metastases, and clean lymph glands.

Now I’m in the risk group. Another melanoma can appear and most likely will be bigger and faster growing than the first one. I need to check up with my dermatologist every 6 months and avoid long sun exposure.

What I have taken out of this experience is that it is important to be aware of what is going on in my body. Melanoma can be treated much more easily if it’s noticed in time.

Request to connect

Read more

Genevieve’s Story

Montreal, QC

I am 52 years old and I have had a lot of luck; having not met the right people at the right time, I would not be alive to tell you my story.

I am proud to say that I have survived two recurrences of malignant melanoma since my initial diagnosis at forty seven years old.

On December 22, 2011, the doctor called me at work. I had just been promoted to the position of director. The results of a beauty spot that had been removed from my leg came back as T1a melanoma. The doctor planned to make an extended incision for 1 cm and check the sentinel ganglion.

The pathology report came back negative for extended tissue and the sentinel ganglion; I felt very lucky. According to the surgeon, only 20% of T1a melanomas reoccur, so I was not concerned at all. I felt like this episode was an alert, a message to slow down and enjoy life. The kids were old enough now, and I was ready to make a few changes. I took three weeks off work to recover from surgery.

On the fifth day of our cruise to the Bahamas in October 2014, I felt a big nodule in my groin area of the same leg. I knew immediately what was happening.

The surgeon removed seventeen ganglions. Two of them were positive for melanoma, but one was over 3 cm and was extending over the capsula. I received one year of Interferon treatment, over one hundred and twenty extremely painful injections. I took nine months off work and worked under Interferon to be able to pay the bills and the extra for this expensive treatment.

In November 2015, we were very close to the end of Interferon treatment. A PET scan showed multiple lung metastasis. My life expectancy was less than a year. However, I had the chance of being approved to be a part of a trial for a new chemo available in Quebec from September 2015 onwards.

Currently, I have been receiving chemotherapy every second week since December 8, 2015, and will receive it for life with the help of Bristol-Myers. I have a miraculous happy ending: my scan from July 2016 shows a regression of all the lung metastasis.

Chemotherapy is demanding, the sides effects are painful, but I am alive! I am still unable to work but I am thinking of going back one day per week in the near future! I am living proof that, with the help of the latest treatments (Nivolumab/Opdivo in my case), living with Stage 4 melanoma is now possible.

.

Request to connect

Read more

Chris B’ Story

Kamloops, B.C.

In 2009, I had a mole removed from my back with a wide excision surgery. Though the mole was cancerous, it had been removed completely, so I stopped thinking about it.

I was out hiking in May 2015, when I began to feel surprisingly short of breath. I went in for an x-ray, and the doctor told me to go to the hospital immediately; my right lung had almost collapsed. The melanoma had moved into the pleura lining of my lung, causing fluid leakage. I spent ten days in the hospital, with a chest catheter draining my lung fluids regularly.

I then had a bronchial tube biopsy, the results of which came back as stage 4 metastatic melanoma. CT scans founds more tumours on my kidney, spine, and neck. I travelled to Kelowna to begin receiving the checkpoint inhibitor combination of Tafinlar and Mekinist. By September, I had begun to feel better; however, my body became immune to the drugs I was receiving, and my cancer came back.

I began seeing a Naturopath, who suggested I look into the immunotherapy combination of Nivolumab and Ipilimumab. When my cancer returned, I was admitted to the hospital in Kamloops, waiting for my Oncologist to decide between the immunotherapy Keytruda, or finding a clinical trial for Nivolumab and Ipilimumab. He found a trial in Edmonton, where I went, despite being very ill. During the first round of treatment, I was constantly dehydrated, despite draining three litres of fluid a day from my body. After the second round, I began to feel better. I spent six and a half weeks in the Cross Cancer Institute, taking pain relief medications and having fluid drained regularly from my lungs. After my fourth cycle of treatment, I was discharged from the hospital. While I still have nine treatments to go of Nivolumab, which I receive every second week, I am on track for a full immune response.

Request to connect

Read more

Merck and Pfizer Collaborate on Potential Merkel Cell Carcinoma Treatment

Merkel cell carcinoma (MCC) is a rare form of skin cancer, making up fewer than 1% of all non-melanoma skin cancers (Canadian Cancer Society, “Merkel Cell Carcinoma”). It manifests as malignant cells that form in the upper layer of skin, near the nerve endings that sense touch (Merck-Pfizer Alliance, “Merkel Cell Carcinoma Fact Sheet”). Merkel cell carcinoma often appears on sun-exposed areas of the skin, such as the legs, arms, neck, and head, as a blue or red lump on the skin. It most frequently occurs in fair-skinned males over 50 years of age (Merck-Pfizer Alliance).

Merkel cell carcinoma has a higher mortality rate than melanoma, with a mortality rate of 33% within five years of diagnosis (all stages) (Merck-Pfizer Alliance). Due to low awareness of merkel cell carcinoma, late diagnosis often results in the disease having reached stage III or IV(Merck-Pfizer Alliance).

Current treatment options for merkel cell carcinoma include chemotherapy, radiotherapy and surgery. These treatments are generally ineffective for advanced stage merkel cell carcinoma, resulting in a mortality rate of roughly 80% for stage IV metastatic merkel cell carcinoma patients (Merck-Pfizer Alliance). There is a gap in treatments for merkel cell carcinoma, and a need for more research and the staging of clinical trials to fill that gap.

Fortunately, at least one new treatment is in the works. JAVELIN merkel 200 is the title of an ongoing clinical study investigating the effects of avelumab, a treatment jointly manufactured by pharmaceutical developers Merck (Germany) and Pfizer (USA), on pre-treated patients with merkel cell carcinoma. The treatment inhibits PD-L1 interactions (Pharmaceutical Technology, “Merck and Pfizer’s Avelumab gets Breakthrough Status for Merkel Cell Carcinoma”), acting as an immune checkpoint inhibitor. The trial produced the largest set of data, in this patient population, of any anti-PD-L1/PD-1 (Pfizer, “ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma”). The results reported at the 52nd annual American Society of Clinical Oncology (ASCO) in Chicago this past June were promising: of 88 patients, 28 (31.8%) demonstrated an objective response rate during the Phase II study of avelumab (Pfizer). Of those that responded, 8 (9.1%) achieved complete responses, with 20 (22.7%) achieving partial responses (Pfizer). Of the entire trial, 62 (70.5%) patients experienced treatment related adverse effects (AEs), with the most common being fatigue (23.9% of patients) and infusion-related reactions (17%), with four patients (4.5%) experiencing grade 3 side effects and zero with grade 4 side effects (Pfizer). The ages of the trial participants ranged from 33-88 years old, and every participant had been pre-treated with chemotherapy (Pfizer). The patients received 10mg/kg of treatment intravenously every two weeks (Pfizer).

While avelumab is still in the trial stage, if it is approved, it will be the first approved treatment for Merkel Cell Carcinoma. Current information about the status of the trial can be found on the American clinical trial database or Pfizer’s website.

 
Works Cited:

Canadian Cancer Society, “Merkel Cell Carcinoma”.

Merck-Pfizer Alliance, “Merkel Cell Carcinoma Fact Sheet”.

Pfizer, “ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma”.

Pharmaceutical Technology, “Merck and Pfizer’s Avelumab gets Breakthrough Status for Merkel Cell Carcinoma”.

Read more

Save Your Skin Weekly Flashback! [Sept 5-11]

Welcome to the Save Your Skin Foundation media flashback- your weekly guide to the melanoma landscape, and the activities of the Save Your Skin Foundation! This week, we are excited to point you towards the most recent publication Save Your Skin has been involved in, CONSENSUS REPORT: Recognizing non-melanoma skin cancer, including actinic keratosis, as an occupational disease- A Call to Action,” in the Journal of the European Academy of Dermatology and Venereology! We’d also like to remind you of our next event, our “Mountain or Mole Hill?” skin cancer forum in Nanaimo, BC, on October 6th! Details can be found in the banner below.

 

PatientForumPoster_Oct2016

 

Here are some links we shared with you this week:

-A reminder to check out our “Melanoma Through my Lens” project, if you haven’t already!

This blog post by Doris Day, M.D., about the importance of sunscreens and choosing the right one for you

This Centers for Disease Control and Prevention guide to sun safety for children, which includes resources about sun safety for students

This article from the Canadian Cancer Society’s Research Information Outreach Team about the emergence of oncolytic virus therapy

This story in The Globe and Mail about Dr. Brian Day’s fight to lift the ban on paid-for private health care for “medically necessary” care

 

Thanks for reading, and be sure to stay sun safe even when the weather is cooling off!

MelanomaThroughMyLens_Banner

Read more

Event: The Third Annual Bill Fox Memorial Golf Tournament

Looking to golf for a good cause? If you’re in the Granton, Ontario area, check out the third annual Bill Fox Junior Memorial Golf Tournament! Held on September 10 at the Fox Golf Club, the event will honour late CPGA professional golfer Bill Fox, who passed away at fifty years old from melanoma. Since 2014, the Save Your Skin Foundation has collaborated with the tournament to ensure sun safety on the day, and promote melanoma and sun safety awareness. The tournament will consist of a shotgun scramble with teams of four, and a passport for purchase that allows participants to take part in the longest drive, closest to the pin, and other contests! The winning team will have their names engraved on the Bill Fox memorial trophy, which remains at The Fox year round. Registration fees include the cart, range balls, a hot dog lunch (with a drink ticket!), and a ticket to the steak dinner and silent auction that will round off the evening! Tickets for the dinner can be purchased individually without participation in the tournament. If you’re a golfer in the area, come out for a good cause- and don’t forget your sunscreen!

 

*Vegetarian option for dinner available upon request.

All skill levels are welcome.

Registration Deadline: September 3rd.

Registration is $115 per person.

Register at: 519-225-2757 or billfoxgolftournament@gmail.com

Registration deadline is August 10.

Tickets for dinner only available for $35.

Read more

Save Your Skin Weekly Flashback! [August 28th-September 4th]

Welcome to the Save Your Skin Foundation media flashback- your weekly guide to the melanoma landscape, and the activities of the Save Your Skin Foundation! First off, we’d like to thank everyone who has tuned in to our last webinars, a post-ASCO review with Dr. Omid Hamid, and “Choosing the Right Sunscreen” with Renée-Claude Lachapelle! If you are interested in learning more about melanoma and are located on Vancouver Island, we’d love to see you at the forum we are running on October 6th in Nanaimo, B.C., with our friends at La Roche-Posay and Leo Pharma! It will be hosted by Dermatologist Dr. Gabriele Weichert, and melanoma survivors Nigel Deacon and Meloney Edghill! More details can be found in the banner below.

 

PatientForumPoster_Oct2016

 

Here are some links we shared with you this week:

-These amazing New York Times articles covering the emergence of immunotherapy and the story of one man’s intensive treatments

This piece in BC Cancer Foundation’s Partners in Discovery about NeTracer, a radionuclide therapy program that is set to begin in BC within the year

This video on Oncology Tube in which Dr. Omid Hamid discusses the future of immunotherapy and new clinical trials

This piece in News Medical about iris melanoma- Always wear sunglasses!

These sun safety tips from Doctors Nova Scotia

This piece on Dr. Yvette Lu’s blog debunking sun safety myths

This American Academy of Dermatology guide to skin self exams

These sun safety tips from Sunburn Alert

This Express article about the dangers of burning while driving

This Aim at Melanoma Foundation guide to a skin self-exam

 

Thanks for reading! Remember to keep checking the UV index to see if you should be wearing sunscreen, even as the weather turns more grey!

syshandinhand

Read more